Brilliant Violet 421™ anti-human CD197 (CCR7
- 产品名称：
- Brilliant Violet 421™ anti-human CD197 (CCR7
- 产品类别：
- 抗体
- 产品编号：
- 353207
- 产品应用：
- 353207
- Verified Reactivity
- Human
- Reported Reactivity
- African Green, Baboon, Cynomolgus, Rhesus
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Immunogen
- CCR7-transfected cells
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.
Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet?.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. - Excitation Laser
- Violet Laser (405 nm)
- Product Citations
-
- Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed
- Jiang XL, et al. 2021. Nat Commun. 12:897. PubMed
- Ols S, et al. 2020. Cell Reports. 30(12):3964-3971. PubMed
- Eslamizar L, et al. 2021. NPJ Vaccines. 6:15. PubMed
- Karlsson H, et al. 2015. PLoS One. 10: 0144787. PubMed
- Cassotta A, et al. 2019. Nat Med. 25:1402. PubMed
- Spandan V Shah et al. 2018. Cell reports. 25(10):2766-2774 . PubMed
- Ahmed R, et al. 2020. Cell Rep. 33:108501. PubMed
- Mandolesi M, et al. 2021. Cell Reports Medicine. 2(4):100252. PubMed
- Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
- Pan YG, et al. 2021. Immunity. 54(6):1245-1256.e5. PubMed
- Ramaswamy A, et al. 2021. Immunity. 54(5):1083-1095.e7. PubMed
- Szabo PA, et al. 2021. Immunity. 54(4):797-814.e6. PubMed
- van der Ploeg K, et al. 2022. Cell Rep Med. 3:100640. PubMed
- Wallin J, et al. 2016. Nat Commun. 7:12624. PubMed
- Geiger R, et al. 2016. Cell. 167:829-842. PubMed
- Bovay A, et al. 2020. Hum Vaccin Immunother. 16:3103. PubMed
- Azeem W, et al. 2021. Biomedicines. 9: . PubMed
- Yu C, et al. 2021. Med (N Y). 2:755. PubMed
- Richert-Spuhler LE, et al. 2021. Cell Reports Medicine. 2(6):100322. PubMed
- Thompson EA, et al. 2019. Cell Rep. 28:1127. PubMed
- Siddiqui I et al. 2019. Immunity. 50(1):195-211 . PubMed
- Pais Ferreira D, et al. 2020. Immunity. 53(5):985-1000.e11. PubMed
- Grifoni A, et al. 2020. Cell. 181(7):1489-1501.e15.. PubMed
- Barcelo H, et al. 2018. Curr Protoc Cytom. 84:e35. PubMed
- Cassotta A, et al. 2020. J Exp Med. 217:00:00. PubMed
- Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
- Port JR, et al. 2020. J Virol. 94:. PubMed
- Bziat V, et al. 2021. Cell. . PubMed
- Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed
- Dai Z, et al. 2022. Signal Transduct Target Ther. 7:85. PubMed
- Waddington KE, et al. 2020. Front Immunol. 1.51875. PubMed
- Halkias J, et al. 2019. J Clin Invest. 130:3562. PubMed
- Marcandalli J et al. 2019. Cell. 176(6):1420-1431 . PubMed
- Georg P, et al. 2022. Cell. 185:493. PubMed
- Neumann B, et al. 2015. J Leukoc Biol. 97:19. PubMed
- Rosato PC, et al. 2019. Nat Commun. 10:567. PubMed
- Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
- Gustafson CE, et al. 2020. JCI Insight. 5:. PubMed
- Azeem W, et al. 2020. Front Immunol. 11:438. PubMed
- Thyagarajan B, et al. 2018. J Immunol Methods. 463:61. PubMed
- Nobs SP, et al. 2017. J Exp Med. 214:3015. PubMed
- Abd Hamid M et al. 2019. Cancer Immunol Res. 7(8):1293-1306 . PubMed
- Fu J, et al. 2021. J Clin Invest. 131:. PubMed
- Benner M, et al. 2020. Cell Rep. 32:108204. PubMed
- Darrah PA, et al. 2019. NPJ Vaccines. 4:21. PubMed
- Vadaq N, et al. 2022. iScience. 25:105089. PubMed
- Grutza R, et al. 2020. J Immunol. 204:2910. PubMed
- Cassotta A, et al. 2020. Eur J Immunol. . PubMed
- Gerna G, et al. 2015. J Gen Virol. 96:360. PubMed
- RRID
- AB_10915137 (BioLegend Cat. No. 353207) AB_11203894 (BioLegend Cat. No. 353208)
- Structure
- Chemokine receptor, G protein-coupled receptors (GPCR), seven transmembrane receptor.
- Distribution
-
T cells, B cells, NK, dendritic cells.
- Function
- The chemokine receptor CCR7 plays a pivotal role in the homing of na?ve T cells and regulatory T cells to secondary lymphoid organs, and the migration of dendritic cells into afferent lymphatic vessels.
- Ligand/Receptor
- CCL19 and CCL21.
- Cell Type
- B cells, Dendritic cells, NK cells, T cells
- Biology Area
- Immunology
- Molecular Family
- CD Molecules, Cytokine/Chemokine Receptors, GPCR
- Antigen References
-
1. Yanagihara S,?et al.?1998.?J. Immunol.?161:3096.
2. Charo IF,?et al.?2006.?N. Engl. J. Med.?354:610.
3. Reif K,?et al.?2002.?Nature?416:94.
4. Nakata B,?et al.?2008.?Oncology?74:69.
5.?Brodie T.?et al. 2013.?Cytometry A.?6: 530-2.?PubMed
6. Graves A.J. et al. 2014. Cytometry A. 7: 576–9?PubMed
7. Moncunill G. et al. 2014. Cytometry A. 12: 995-8?PubMed
- Gene ID
- 1236 View all products for this Gene ID
- UniProt
- View information about CD197 on UniProt.org
